Delivery Order SPE2DB22D3019-SPE2DB24FK3SD

Award Date 8/6/24
Potential Completion Date 8/7/24
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of LOTREL 10-20 mg capsules. The award, with a ceiling value of $10,628.38, has a period of performance through September 5, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999, to provide a wide range of medical commodities, including...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of $81,406.88 worth of LOTREL 10-20 MG CAPSULE 100S. This delivery order falls under an indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
This federal contract award is for the delivery of LOTREL 10-20 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The $31,072.83 Firm Fixed Price contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on July 26, 2024 with a completion date of July 29, 2024. The contract is a Delivery Order and is not associated with any set-aside designation. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award is to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the supply of LOTREL 10-20 MG CAPSULE 100S to the Defense Logistics Agency (DLA) Troop Support Medical. The firm-fixed price delivery order, valued at $23,725.76, has an ultimate completion date of August 30, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,741.48 firm fixed-price delivery order is for the supply of LOTREL 10-20 MG CAPSULE 100S, a cardiovascular medication. The contract has an ultimate completion date of November 22, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,461.64, is for the delivery of 4562538247 LOTREL 10-20 MG CAPSULE 100S. The contract type is a Delivery Order with a Firm Fixed Price pricing structure and an ultimate completion date of October 20, 2023. The contract was awarded on October 19, 2023 and does not have a...
This federal contract award is for the delivery of LOTREL 10-20 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The contract has a ceiling value of $19,585.71 and is a Firm Fixed Price Delivery Order. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of September 17, 2024 and was awarded on September 16, 2024. The contract was not set aside for any specific business...
This federal contract award is for the delivery of LOTREL 10-20 MG CAPSULE 100S, a pharmaceutical product, to the Medical Supply Chain, which is an alternate name for the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract, valued at $1,896.41, is a delivery order with a firm-fixed price pricing type. It has an ultimate completion date of November...
This federal contract award is for the delivery of Lotrel 10-20 mg capsules to the Defense Logistics Agency (DLA). The $20,780.76 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of May 13, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $38,749.29 firm fixed-price delivery order is for the supply of LOTREL 10-20 MG CAPSULE 100S, a cardiovascular medication. The contract has an ultimate completion date of January 27, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
  • SPE2DB22D3019
    Indefinite Delivery Contract
  • SPE2DB22D3019-SPE2DB24FK3SD
    Delivery Order

The Defense Logistics Agency (DLA) awarded a $10,580.70 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of LOTREL 10-20 MG CAPSULE 100S. This contract is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has no set-aside designation and is intended to deliver the required pharmaceutical product by August 7, 2024.

Generated 11/5/24, 9:10 AM